Enpatoran, a Toll-like receptor 7/8 inhibitor, in moderate-to-severe systemic lupus erythematosus: findings from Cohort B of a multicentre, international, double-blind, placebo-controlled dose-finding phase 2 trial

This study aimed to evaluate the efficacy and safety of enpatoran, a TLR7/8 inhibitor, in improving disease activity in patients with moderate-to-severe systemic lupus erythematosus (SLE) compared to placebo. Although enpatoran showed improved British Isles Lupus Assessment Group-based Composite Lupus Assessment (BICLA) response rates at various doses, the primary objective of demonstrating a statistically significant dose-response relationship was not achieved. Overall, enpatoran was well tolerated among participants.